- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 213/42 - Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
Patent holdings for IPC class C07D 213/42
Total number of patents in this class: 131
10-year publication summary
|
7
|
13
|
12
|
12
|
4
|
9
|
5
|
10
|
2
|
2
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Bristol-myers Squibb Company | 4757 |
8 |
| F. Hoffmann-La Roche AG | 7796 |
4 |
| Takeda Pharmaceutical Company Limited | 2698 |
4 |
| The University of Melbourne | 572 |
4 |
| Grey Wolf Therapeutics Limited | 17 |
4 |
| The Johns Hopkins University | 5929 |
3 |
| Ranbaxy Laboratories Limited | 258 |
3 |
| Gliapharm SA | 19 |
3 |
| Mitsui Chemicals Crop & Life Solutions,Inc. | 175 |
3 |
| BASF SE | 21328 |
2 |
| Massachusetts Institute of Technology | 10290 |
2 |
| Artizan Biosciences, Inc. | 9 |
2 |
| Concert Pharmaceuticals, Inc. | 242 |
2 |
| The Governing Council of The University of Toronto, | 1548 |
2 |
| Jazz Pharmaceuticals Ireland Limited | 174 |
2 |
| Kanto Kagaku Kabushiki Kaisha | 93 |
2 |
| Nissan Chemical Industries, Ltd. | 1633 |
2 |
| Oryzon Genomics S.A. | 103 |
2 |
| Sealife Pharma GmbH | 8 |
2 |
| University of Oregon | 210 |
2 |
| Other owners | 73 |